Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nov 15, 2021- Abbott included on DJSI for 17 consecutive years for strong environmental, social and governance (ESG) performance- Top score in the Health Care Equipment & Supplies sector reflects Abbott's 2030 Sustainability Plan focus on innovating for greater access to life-changing technologies and breaking down barriers to health equity- Nov 12, 2021-- New, late-breaking data from the Leadless II IDE study confirm the Aveir™ leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms-- Abbott's Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed-- Abbott's investigational Aveir leadless pacemaker is currently being evaluated for FDA approval
-
Nov 10, 2021- One in four physicians surveyed feel the "lack of technology or equipment to make an accurate diagnosis of coronary artery disease and peripheral artery disease" is a key obstacle to an accurate diagnosis- Over a third of surveyed patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described "confusion about what I was supposed to do next" as an important barrier to early and accurate diagnosis- Socioeconomic status, age and gender in underserved communities are contributing factors that impact patients’ access to care
- Nov 9, 2021- First program to launch under American Diabetes Association's Health Equity Now™ platform- Community program seeks to understand how to increase access to health technology for underserved diabetes communities
- Nov 3, 2021- Abbott is addressing a key challenge to health equity by putting a greater focus on breaking down the barriers to clinical trial participation for under-represented groups- Company has dedicated $5 million for nearly 300 new scholarships over the next five years at medical schools at historically black colleges and universities (HBCU's) and minority nursing associations to support future generations of diverse clinical investigators- The company has also formed a new Diversity in Research Medical Advisory Board and dedicated funding to increase diversity enrollment within Abbott trials- The latest initiative is another step to support the work the company and its Foundation, the Abbott Fund, are doing to reduce health disparities around the world
- Oct 20, 2021- Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent- GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent- Global COVID-19 testing-related sales were $1.9 billion in the third quarter- Excluding COVID-19 testing-related sales, third-quarter sales grew 11.7 percent on both a reported and organic basis compared to sales in 2019- Continues to strengthen portfolio with several new product approvals
- Oct 18, 2021- Abbott becomes Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation- Partnership will include support of the first men's and women's and Academy football teams as well as support of the Real Madrid Foundation- Foundation supports 65,000 children per year across 80 countries through education in sportsmanship, teamwork, respect, and health and nutrition- Partnership supports Abbott's commitment to address global malnutrition over the next decade
- Sep 30, 2021- Abbott is investing $45 million annually to help identify, treat and prevent malnutrition- Innovation hub will focus on reducing malnutrition for the most vulnerable populations in the world
-
Sep 29, 2021- Talisman system builds on the minimally invasive Amplatzer PFO Occluder, the world's leading patent foramen ovale (PFO) closure device that has been used to treat more than 180,000 patients worldwide- Abbott’s PFO closure technology helps to prevent blood clots from passing from the right to left side of the heart from where they can travel to the brain and cause a stroke- The Talisman system offers the industry's widest range of device sizes in the U.S. and the occluder comes pre-attached to the delivery cable, making the device easier for physicians to use